Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01613703 · ClinicalTrials.gov registry record · Phase 1
ONO-2952 Single-dose PET Study in Healthy Adult Subjects
A Phase 1 study, sponsored by Ono Pharma USA.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT01613703 is a Phase 1 study that has completed, run by Ono Pharma USA. The registered enrollment target is 16 participants.
The verdict
NCT01613703, a Phase 1 study, has completed, sponsored by Ono Pharma USA.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate the brain TSPO occupancy of ONO-2952 in healthy adult subjects after a single dose using \[11C\]PBR28 as a specific PET ligand for TSPO. The secondary objective is to evaluate the relationship between TSPO occupancy and the plasma concentration of ONO-2952 and to investigate the safety and tolerability of ONO-2952 in healthy subjects.
Interventions
- DRUG ONO-2952
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2012-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01613703
The ClinicalTrials.gov registry entry for NCT01613703 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ono Pharma USA, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ONO-2952 is the first listed.
NCT01613703 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01613703 about?
NCT01613703 is a clinical study titled "ONO-2952 Single-dose PET Study in Healthy Adult Subjects". The primary objective of this study is to evaluate the brain TSPO occupancy of ONO-2952 in healthy adult subjects after a single dose using \[11C\]PBR28 as a specific PET ligand for TSPO. The secondary objective is to evaluate the relationship between TSPO occupancy and the plasma concentration of O...
What is the current status of trial NCT01613703?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2012-08.
What interventions are being tested in trial NCT01613703?
The interventions under investigation include: ONO-2952 (DRUG).
Who is sponsoring clinical trial NCT01613703?
This trial is sponsored by Ono Pharma USA, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.